OSSDSIGN Aktie

 

Uppsala, Sweden, December 5, 2025. OssDsign AB (publ.) today announces that the company has signed an agreement with an IDN (Integrated Delivery Network) in the Western U.S. marking the company's most significant opportunity for sales growth in the region to date. The agreement allows IDN member hospitals and clinics, at their discretion, to take advantage of special pricing and pre-negotiated terms for OssDsign's nanosynthetic bone graft OssDsign Catalyst®. Since entering the orthobiologics business late 2021, the company has had a natural gravity towards the Eastern U.S.; however, during...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Record breaking sales month and best quarterly EBIT result OssDsign AB (publ) announces that the interim report for Q3 2025 is now available as a PDF on the company's website www.ossdsign.com/reports. A PDF version is also attached to this press release. The Q3 2025 results will also be presented at an investor webcast today November 4th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q3-2025/ or via the OssDsign website. The third quarter in figures · Net sales amounted to TSEK 44,020 (35,728), which translates to a growth...

Uppsala, Sweden, September 2, 2025. OssDsign AB (publ.) today announces that a case study of OssDsign Catalyst® as a bone void filler to augment total ankle arthroplasty in a patient with post-traumatic ankle arthritis has been published in the Biomedical Journal of Scientific & Technical Research. The rationale for the use of Catalyst Bone Graft for this patient, in addition to its ease of handling for the surgeon, was related to its mechanism of action, which includes both endochondral and intram­embranous ossification. The authors conclude that at three months follow up, CT scans show...

Die schwedische Medtech-Gesellschaft OssDsign kann am Dienstag mit starken Zahlen zum zweiten Quartal brillieren. Das Unternehmen, welches 2011 auf der auf Grundlage einer Zusammenarbeit zwischen der Universität Uppsala und der Karolinska-Universität gegründet wurde, verzeichnete erneut ein starkes Wachstum mit Traum-Margen....

Extraordinary real-world clinical data and strengthened balance sheet to launch new "ScaleToProfit” growth strategy OssDsign AB (publ) announces that the interim report for Q2 2025 is now available as a PDF on the company's website www.ossdsign.com/reports. A PDF version is also attached to this press release. The Q2 2025 results will also be presented at an investor webcast today August 19th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q2-2025/ or via the OssDsign website. The second quarter in figures · Net sales...

GB00BYWQCY12 SE0003883008 AU0000187569 JP3273810006 CA05478A2083 SE0008040653 VGG6769T1158 IT0005434615 AU0000180200 CA55877M1059 CA21872J3073 CA9013201012 SE0006758587 SE0022447348 CA0249441001 CA48344L1076 FI0009007991 IT0000070786 HK0154000803 IT0005241192 SE0012570448 SE0005308541 SE0005100757 CA37452L1085 AU0000315624 CA50012K1066 CA88105E1088 CA02527W2085 CA87310A1093 SE0025158629 SE0006219473 CA08772P2026 CA7615161030 IT0005337172 BMG1985B1138 CA75602C1077 CA40054T3055 CA00208D4084 SE0012729937 SE0015812417 CA25039N4084 CA76125W5054 CA87618P2044 CA69938P2052 CA00792K1075 CA8968871068 GB00BP371R64 AU0000159840 JE00BMDKH437 CA5651271077 GB00BD0SFR60 IE0003864109 SGXE21011833 AU0000310302 CA29408D1087 AU0000249831 DK0010212570 JP3351100007 SE0009832595 CA77584B1076 CA13515Q1037 CA7481197084 SE0001200015 SE0020354389 CA26886Q1063 AU000000TAR7 CA3485823056 CA71385D1078 CA77519R1029 GB00BYZQM590 AU000000LPD2 SE0020846392 CA06683K1066...

Uppsala, July 1, 2025. OssDsign AB (publ.) announces that the exercise period for the long-term incentive warrant program 2022/2025 starts today on July 1. Approximately 1.5 million warrants have been issued to board members, executives and employees as part of the long-term incentive program adopted at OssDsign's Annual General Meeting in 2022. According to the program, warrants can be exercised to buy shares (1 share per warrant) between July and December 2025. If all warrants are converted to shares, the company will receive approximately SEK 10 million.   In conjunction with the...

STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company's liquidity. The divestments brings Karolinska Development a capital injection of approximately SEK 34.5 million....

Uppsala, June 26, 2025. OssDsign AB (publ.) today announces that the company has published one-year results from the first 108 patients in its prospective, multi-center, spinal fusion registry PROPEL. The results show an outstanding fusion rate of 88.4% in the real-world setting in a highly complex patient cohort, demonstrating that OssDsign Catalyst® shows strong performance even in challenging patient populations with high BMI, previous failed fusion surgeries, smokers, multi-level procedures and several comorbidities. “Typically, I would expect to see dramatically lower fusion rates for...

11 June 2025. Today, the annual general meeting of 2025 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting (complete information and documents regarding the decisions of the meeting are available on the company's website www.ossdsign.com). The annual general meeting resolved:   -        to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2024;   -        that the company's result shall be carried forward in new account and that...

Uppsala, June 9, 2025. OssDsign AB (publ.) today announces, through the nomination committee, a revised proposal for election of the board of directors at the annual general meeting on June 11, 2025. In the notice convening the annual general meeting in OssDsign AB (publ) (the “Company”), to be held on 11 June 2025, the nomination committee proposed re-election of Simon Cartmell (also proposed to be re-elected as chairman), Christer Fåhraeus, Jill Schiaparelli and Newton Aguiar, and new-election of David Jern, as ordinary members of the board of directors.   The nomination committee...

STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding procedure that brought the company approximately SEK 158 million. In connection with the directed share issue, the company announced an updated strategy and revised its financial targets for the period 2025–2028....

June 3, 2025, 23:04 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) has completed a directed share issue of 11,500,000 shares at a subscription price of SEK 13.75 per share (the “Directed Issue”), through which the Company receives approximately SEK 158 million before deduction of transaction costs. The subscription price was determined based on an accelerated book-building procedure lead by DNB Carnegie Investment Bank AB (“DNB Carnegie”). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG,...

June 3, 2025, 19:35 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) earlier today informed that the Company has mandated DNB Carnegie Investment Bank AB (“DNB Carnegie”) to evaluate the conditions for carrying out a new share issue of approximately 9 million shares directed towards Swedish and international institutional investors (the “Directed Share Issue”). The interest in participating in the Directed Share Issue has been strong and OssDsign has therefore decided to investigate the conditions for increasing the scope to approximately 11.5 million shares. NOT FOR RELEASE,...

June 3, 2025, 17:31 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) intends to explore the conditions to carry out a directed share issue corresponding to approximately nine million shares through an accelerated bookbuilding procedure to Swedish and international institutional investors (the “Directed Issue”), starting immediately. OssDsign has engaged DNB Carnegie Investment Bank AB  (“DNB Carnegie”) to act as Sole Bookrunner in connection with the Directed Issue. In connection with the Directed Share issue, OssDsign announces an updated strategy, “ScaleToProfit”, together with...

Uppsala, May 14, 2025. Today, OssDsign AB (publ.) today announces that the company's share will be included in the MSCI Global Micro Cap Index, implemented as of the close of May 30, 2025. MSCI provides decision support and services to the global investment community and conducts quarterly updates of its equity indexes. In the latest revision, OssDsign has been included in the MSCI Global Micro Cap Index, implemented as of the close of May 30. Based on MSCI's expertise in research, data and technology, equity indexes of global shares are revised continuously to support clients' investment...

OssDsign AB (publ) announces that the Annual Report for 2024 is now available as a PDF on the company's website, www.ossdsign.com. A PDF version is also attached to this press release. “Despite operating in a highly competitive market, we have shown there are vast growth opportunities when offering state-of-the-art innovation that solves the clinical challenges” said Morten Henneveld, CEO, OssDsign AB.   For further information, please contact: Morten Henneveld, CEO, OssDsign AB Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com   Certified Adviser The Company's...

STOCKHOLM, SWEDEN, May 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has reached a new milestone with 10,000 patients treated with the innovative nanosynthetic bone graft OssDsign Catalyst on the US market....

The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 1:00 pm on Wednesday 11 June 2025 at Setterwalls Advokatbyrå's offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting. The board of directors has decided, pursuant to Chapter 7, Section 4, Paragraph 2 of the Swedish Companies Act and the company's articles of association, to apply the possibility of proxy collection in conjunction with the general meeting (se section Proxy collection below for more...